| Control (n = 12) | Sepsis (n = 27) | COVID-19 (n = 6) |
---|---|---|---|
Age | 59 (20–79) | 67 (40–85) | 65 (49–78) |
Male:female | 5:7 | 17:10 | 4:2 |
SAPS II score | n/a | 68.8 (35–99) |  |
BMI (kg/m2) |  | 26.9 (20.8–49) | 30.8 (26–37) |
 Normal weight (BMI 18.5–24.9) |  | 9 | 0 |
 Overweight (BMI 25–29.9) |  | 14 | 3 |
 Obese (BMI > 30) |  | 4 | 3 |
Days in ICU | n/a | 3.6 (1–12) | 30 (21–53) |
Comorbidities | Â | Â | Â |
 Hypertension | 3 | 8 | 1 |
 Diabetes Mellitus | 1 | 3 | 2 |
 COPD or asthma | 4 | 7 | 0 |
 Coronary disease | 1 | 5 | 0 |
 Neurological | 1 | 3 | 0 |
 Renal disease | 0 | 0 | 0 |
 Vascular surgery | 0 | 2 | 0 |
 Autoimmune disease | 2 | 4 | 0 |
 Neoplasms (extra renal) | 4 | 4 | 0 |
RIFLE stage | |||
 Risk | n/a | 0 | n/a |
 Injury | n/a | 12 | n/a |
 Failure | n/a | 15 | n/a |
 Loss of function | n/a | 0 | n/a |
 End-stage renal disease | n/a | 0 | n/a |
KDIGO AKI score | |||
 0 | n/a | n/a | 1 |
 1 | n/a | n/a | 0 |
 2 | n/a | n/a | 0 |
 3 | n/a | n/a | 5 |
Need for RRT (Yes:no) | n/a | 12:15 | 4:2 |
Mean biopsy time (mins) | n/a | 33 (24–150) | 21 (6–40) |
Microorganisms | |||
 Gram positive | n/a | 12 | 3# |
 Gram negative | n/a | 23 | 1* |
 Virus (norovirus & HIV) | n/a | 2 | 0 |
 Fungi/yeast | n/a | 5 | 0 |
 SARS-CoV-2 | n/a | n/a | 6 |